Travere Therapeutics Inc Stock Price, News & Analysis

Travere Therapeutics (NASDAQ: TVTX) is set to release its first quarter 2023 financial results on May 4, 2023, following the close of U.S. markets. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on its business. Interested parties can access the information on the Investor page of Travere’s website. Travere Therapeutics focuses on developing therapies for rare diseases, emphasizing its commitment to supporting patients and families facing these challenges. This upcoming earnings release may provide insights into the company’s financial health and strategic direction, crucial for stakeholders and investors.

Travere Therapeutics has announced the grant of inducement equity awards to five new employees, with a total of 30,000 restricted stock units (RSUs) issued on April 10, 2023. These RSUs, which are part of the 2018 Equity Incentive Plan, are specifically intended to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule for these RSUs spans four years, with 25% vesting on each anniversary, contingent upon the employees maintaining their service with the company.

Travere Therapeutics is dedicated to developing therapies for rare diseases, focusing on patient needs and community involvement to improve treatment outcomes.

Travere Therapeutics (TVTX) announced significant findings from the interim analysis of the Phase 3 PROTECT Study for FILSPARI™ (sparsentan), published in The Lancet. The data showed a mean reduction in proteinuria of 49.8% after 36 weeks of treatment with FILSPARI, contrasting sharply with a 15.1% reduction for irbesartan (p<0.0001). Moreover, 20.8% of patients on FILSPARI achieved complete remission, versus 7.9% for irbesartan (p=0.0005). The results indicate FILSPARI's potential for long-term benefits on kidney function and confirm its favorable safety profile, with adverse events comparable to irbesartan. Topline results for the study's confirmatory analysis are expected in Q4 2023.

Travere Therapeutics (NASDAQ: TVTX) will participate in two upcoming conferences. The first is the Guggenheim Healthcare Talks scheduled for April 4, 2023, at 3:55 p.m. ET. The second is the BofA Securities 2023 Health Care Conference on May 10, 2023, at 3:40 p.m. PT. Live webcasts of both presentations will be available on the company's Investor page, and replays will be accessible for up to 30 days post-event. Travere is dedicated to developing therapies for rare diseases, working closely with patients and the healthcare community to address urgent treatment needs.

Travere Therapeutics (NASDAQ: TVTX) announced that interim efficacy and safety data from the Phase 3 PROTECT Study of FILSPARI™ (sparsentan) for IgA nephropathy (IgAN) will be presented at the ISN World Congress of Nephrology in Bangkok (March 30-April 2, 2023) and NKF Spring Clinical Meetings in Austin (April 11-15, 2023). FILSPARI has received U.S. accelerated approval to reduce proteinuria in IgAN patients at risk of rapid progression. The company will share findings on patient populations and long-term data from the DUET Study of sparsentan in focal segmental glomerulosclerosis (FSGS). Key presentations will highlight significant clinical trial results.